The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Biological profiling in CLL: which emerging markers are changing management?
Richard Rosenquist, MD, PhD, Karolinska Institute, Solna, Sweden, discusses the current state of biological profiling in chronic lymphocytic leukemia (CLL), highlighting established markers used in clinical practice and included in guidelines. Prof. Rosenquist notes that other markers, including complex karyotype and specific mutations like IGHV3-21 R110, are being researched and may have potential as prognostic tools, but require further definition and study. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, so during this session we discussed established markers like the IGHV gene mutation status, TP53 mutations and deletional 17p which are used today and included in the guidelines recommendation. So it’s important to do these markers and you should do them before the start of first treatment but also at subsequent rounds of treatment. We were also discussing other markers that are discussed like complex karyotype...
Yes, so during this session we discussed established markers like the IGHV gene mutation status, TP53 mutations and deletional 17p which are used today and included in the guidelines recommendation. So it’s important to do these markers and you should do them before the start of first treatment but also at subsequent rounds of treatment. We were also discussing other markers that are discussed like complex karyotype. This is a more complex marker that you can detect with traditional cytogenetics or with array technology so it appears that this marker is we still need to define it further so for the time being it’s recommended to be included in clinical studies but not in routine practice then we had other markers for instance the specific marker IGHV3-21 R110 mutation that seems to identify a proportion of cases with very poor outcome and we I would say that it’s still discussed we can see it’s a poor risk marker and it would be possible to detect it but we are still not ready to include it.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
